# Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

> **NCT05515796** · PHASE2 · COMPLETED · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 189 (actual)

## Conditions studied

- Immunotherapy
- Gastric Cancer
- Rectal Cancer
- Chemotherapy Effect
- Radiotherapy

## Interventions

- **DRUG:** Terelizumab (aka Tislelizumab)
- **DRUG:** CapeOx
- **DRUG:** Trastuzumab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT05515796
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-01
- **Primary completion:** 2026-03-25
- **Final completion:** 2026-03-25
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05515796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05515796, "Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05515796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*